Please login to the form below

ICS

This page shows the latest ICS news and features for those working in and with pharma, biotech and healthcare.

AZ prepares to file COPD triple, taking on rival GSK

The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –

Latest news

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

The real battleground between the two companies is expected to be three-drug combinations for COPD, with an inhaled corticosteroid (ICS) added to the LAMA/LABA duo.
AZ’s COPD triple data sets up market clash with GSK

on LABA vilanterol, LAMA umeclidinium and ICS fluticasone furoate - in the US and Europe last year.
EMA approves GSK’s triple COPD therapy

moderate to severe COPD who are not adequately treated by the combination of an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA). ... The same indication was approved by the FDA in September, and makes Trelegy the first drug on the
With US approval, GSK now needs rapid uptake for COPD triple

The three-drug product delivers a long-acting beta agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS) from a single device, and is the first product
GSK closes in on EU approval for triple COPD therapy

The new product adds long-acting muscarinic receptor antagonist (LAMA) umeclidinium to the ICS/LABA combination, which has proved so successful in GSK's big-selling Advair/Seretide (fluticasone propionate/salmeterol) ... The benefits of Trelegy/Elebrato -

More from news
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Deal Watch table for August 2014

600. TARIS Biomedical/ Allergan. Company acquisition. LiRIS for interstitial cystitis / bladder pain syndrome (IC/BPS) (phase II).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

How can pharma engage with key stakeholders on NHS service transformation?

It should also be noted that in the 14 areas, which are early movers from STP to ICS/ICPPs (Integrated Care Provider Partnerships), former low-mid ranking CCG commissioners and project
Raising Awareness: It’s World COPD Day today!

Inhaled corticosteroids (ICS) are another COPD treatment used to reduce inflammation in the lungs. ... Interestingly, no advantage in adding ICS to bronchodilator therapy in patients at low risk of exacerbations has been observed.
Managing local population needs is key for the NHS

year. These plans should “ align key assumptions on income, expenditure, activity and workforce” and system leaders within the ICS are expected to take an “ active role in this process”. ... efficiencies. Conclusion. STPs and the newly emerging
How can pharma engage with key decision-makers in new, collaborative NHS care models?

This has resulted in an increasingly complex, multi-layered healthcare system that is seeing some GPs taking on wide-ranging responsibilities in Integrated Care System (ICS) areas. ... work in an alliance within the ICS.
Large-scale NHS commissioning models require new partnership approach from pharma

Some of the mergers have been entered into voluntarily to help cut costs and ultimately pave the way for the introduction of Accountable or Integrated Care System (ACS/ICS) models; while

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Account Director: Excellent benefits

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Account Director development role to Business Director, H...: Excellent package

Medical/ Scientific Director: Salary TBC

Events Manager – Med Comms – Surrey: Salary TBC

Scientific Director / Editorial Team Leader: Great salary and benefits

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Production Manager – Healthcare Communications: DOE

Associate Director, Market Access & HEOR – North-West: Negotiable

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Medical Writers: Competitive Salary and Benefits

Associate Medical Director: Highly Competitive

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Medical Writers Required – Cheshire: DOE

Senior Medical Writer: Competitive Salary

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Subscribe to our email news alerts

PMHub

Add my company

Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...